EUVIMEDEUVIMED entdecken
Crossref

Durvalumab and T-DXd Synergistically Promote Apoptosis of Cholangiocarcinoma Cells by Downregulating EGR1 Expression Through Inhibiting P38 MAPK Pathway

Yuepeng Wang

Applied Biochemistry and Biotechnology · 2025

DOI: 10.1007/s12010-024-05112-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Applied Biochemistry and Biotechnology, 2025. Verfasst von Yuepeng Wang. Beteiligte Einrichtung: Department of Medical Oncology, Xinglongtai District, Panjin Central Hospital, No.32, Liaohe Middle RoadLiaoning Province 124010, Panjin City, China.…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Apoptosis, Antibodies, Monoclonal, Early Growth Response Protein 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cholangiocarcinoma is a hepatobiliary system tumor with a high mortality rate. Although durvalumab and trastuzumab deruxtecan (T-DXd) have shown efficacy in treating cancers such as non-small cell lung cancer, their effects and regulatory mechanisms in cholangiocarcinoma remain unclear. In this study, we aimed to investigate the role and mechanism of durvalumab and T-DXd in inducing apoptosis in cholangiocarcinoma cells. Cholangiocarcinoma cells were treated with varying concentrations of durvalumab and T-DXd, either individually or in combination, to evaluate their effects. Apoptosis was quantified using flow cytometry. Quantitative real-time PCR (qPCR) and Western blotting were used to measure the mRNA expression and protein levels of genes associated with apoptosis and cell cycle regulation. The underlying mechanism was further explored through pathway enrichment analysis of differentially expressed genes (DEGs) and corroborated by qPCR and Western blotting. Xenotransplantation models using immune-deficient NOD-SCID/IL2Rγnull (NSG) mice were established to assess the in vivo effects of durvalumab and T-DXd. Our results showed that both durvalumab and T-DXd inhibited cholangiocarcinoma cell proliferation in a dose-dependent manner. Both agents promoted apoptosis and arrested the cell cycle of cholangiocarcinoma cells, with the combination treatment having the most significant effect. Furthermore, treatment with durvalumab, T-DXd, and the combination downregulated the protein levels of early growth response 1 (EGR1) by inactivating the p38 mitogen-activated protein kinase (MAPK) pathway. In vivo experiments indicated that durvalumab and T-DXd prolonged the survival of NSG mice bearing cholangiocarcinoma xenografts. In conclusion, our findings demonstrated that durvalumab and T-DXd synergistically promoted apoptosis in cholangiocarcinoma cells by inhibiting EGR1 expression through inactivation of the p38 MAPK pathway. This study confirmed the potential of durvalumab and T-DXd for the treatment of cholangiocarcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaApoptosisAntibodies, MonoclonalEarly Growth Response Protein 1p38 Mitogen-Activated Protein KinasesDown-RegulationBile Duct NeoplasmsMAP Kinase Signaling SystemGene Expression Regulation, NeoplasticAnimalsHumansMiceCell Line, TumorDrug SynergismMice, SCIDMice, Inbred NODXenograft Model Antitumor Assays

Stichwörter der Autor:innen

ApoptosisCholangiocarcinomaDurvalumabEGR1T-DXd

Substanzen

Antibodies, MonoclonalEarly Growth Response Protein 1p38 Mitogen-Activated Protein KinasesdurvalumabEGR1 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Xinglongtai District, Panjin Central Hospital, No.32, Liaohe Middle RoadLiaoning Province 124010, Panjin City, China. wangyuepeng1122@163.com.

Zitieren

APA

Wang, Y. (2025). Durvalumab and T-DXd Synergistically Promote Apoptosis of Cholangiocarcinoma Cells by Downregulating EGR1 Expression Through Inhibiting P38 MAPK Pathway. Applied Biochemistry and Biotechnology. https://doi.org/10.1007/s12010-024-05112-0

Vancouver

Wang Y. Durvalumab and T-DXd Synergistically Promote Apoptosis of Cholangiocarcinoma Cells by Downregulating EGR1 Expression Through Inhibiting P38 MAPK Pathway. Applied Biochemistry and Biotechnology. 2025. doi:10.1007/s12010-024-05112-0

BibTeX
@article{Wang2025,
  author = {Wang, Yuepeng},
  title = {Durvalumab and T-DXd Synergistically Promote Apoptosis of Cholangiocarcinoma Cells by Downregulating EGR1 Expression Through Inhibiting P38 MAPK Pathway},
  journal = {Applied Biochemistry and Biotechnology},
  year = {2025},
  doi = {10.1007/s12010-024-05112-0}
}
Kostenlos starten →